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obesity-associated diastolic dysfunction 
through suppression of ventricular-vascular 
stiffness
Annayya R. Aroor1,2,3, Srinivas Mummidi4, Juan Carlos Lopez‑Alvarenga4, Nitin Das5, Javad Habibi1,2,3, 
Guanghong Jia1,2,3, Guido Lastra1,2,3, Bysani Chandrasekar3,6,7,8* and Vincent G. DeMarco1,2,3,7,8*  
Abstract 
Objective: Cardiac diastolic dysfunction (DD) and arterial stiffness are early manifestations of obesity‑associated pre‑
diabetes, and both serve as risk factors for the development of heart failure with preserved ejection fraction (HFpEF). 
Since the incidence of DD and arterial stiffness are increasing worldwide due to exponential growth in obesity, an 
effective treatment is urgently needed to blunt their development and progression. Here we investigated whether 
the combination of an inhibitor of neprilysin (sacubitril), a natriuretic peptide‑degrading enzyme, and an angiotensin 
II type 1 receptor blocker (valsartan), suppresses DD and arterial stiffness in an animal model of prediabetes more 
effectively than valsartan monotherapy.
Methods: Sixteen‑week‑old male Zucker Obese rats (ZO; n = 64) were assigned randomly to 4 different groups: 
Group 1: saline control (ZOC); Group 2: sacubitril/valsartan (sac/val; 68 mg•kg−1•day−1; ZOSV); Group 3: valsartan 
(31 mg•kg−1•day−1; ZOV) and Group 4: hydralazine, an anti‑hypertensive drug (30 mg•kg−1•day−1; ZOH). Six Zucker 
Lean (ZL) rats that received saline only (Group 5) served as lean controls (ZLC). Drugs were administered daily for 
10 weeks by oral gavage.
Results: Sac/val improved echocardiographic parameters of impaired left ventricular (LV) stiffness in untreated ZO 
rats, without altering the amount of food consumed or body weight gained. In addition to improving DD, sac/val 
decreased aortic stiffness and reversed impairment in nitric oxide‑induced vascular relaxation in ZO rats. However, 
sac/val had no impact on LV hypertrophy. Notably, sac/val was more effective than val in ameliorating DD. Although, 
hydralazine was as effective as sac/val in improving these parameters, it adversely affected LV mass index. Further, 
cytokine array revealed distinct effects of sac/val, including marked suppression of Notch‑1 by both valsartan and sac/
val, suggesting that cardiovascular protection afforded by both share some common mechanisms; however, sac/val, 
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Introduction
Heart failure (HF) with normal or preserved ejection 
fraction (HFpEF) represents a unique pathophysiologi-
cal phenotype which is distinct from HF with reduced 
ejection fraction (HFrEF). In this regard, asymptomatic 
diastolic dysfunction (or preclinical DD) is one of the ear-
liest manifestations during the progression of HFpEF in 
obesity-associated heart disease in both adults and chil-
dren [1–3]. Moreover, the prevalence of DD is high in the 
general population and its incidence is further increased 
in individuals with early phase obesity-associated type 2 
diabetes [4, 5]. In addition to low grade inflammation and 
intrinsic structural and functional abnormalities, vascu-
lar stiffness also contributes to DD development and pro-
gression to HFpEF in obese diabetic individuals [5–9].
There are no evidence-based therapies to treat HFpEF, 
and therefore therapeutic strategies are urgently needed 
to improve cardiovascular outcomes, including DD [10]. 
In this regard, dysregulation of the natriuretic peptide 
(NP) system and inappropriate activation of the Renin–
Angiotensin–Aldosterone System (RAAS) contribute to 
the development of obesity-associated DD in the absence 
of significant impairment in EF, a marker of systolic dys-
function [13–18]. Although high doses of recombinant 
BNP, e.g., Nesiritide, are used in the management of acute 
cardiac dysfunction, their use in treating chronic HF is 
limited due to adverse hemodynamic consequences and 
a requirement for intravenous administration [11–13]. 
Inhibition of the RAAS system is considered as one of 
the therapeutic options for the management of DD, how-
ever, the long-term administration of angiotensin recep-
tor blockers (ARBs) is associated with aldosterone escape 
[14, 15]. To circumvent these side-effects, a new class of 
drug containing the combination of sacubitril, a nepri-
lysin inhibitor that blocks the degradation of NPs, and 
valsartan, an ARB, is increasingly recognized as an ideal 
combination to manage HFrEF [16, 17]. The rationale for 
combining valsartan with sacubitril is to overcome the 
deleterious effects of sacubitril-induced Ang II accumula-
tion [12, 18–20].
A recent clinical trial reported that sacubitril-valsar-
tan (sac/val) did not significantly lower rates of hospi-
talizations for HF and death from cardiovascular disease 
among patients with established HFpEF [21]. However, 
few studies have examined the effects of sac/val to blunt 
the severity of DD in pre- and early diabetic states of obe-
sity-related cardiomyopathy. Recently, sac/val was shown 
to be superior to val at preventing the onset of DD in a 
preclinical model of diet-induced obesity [22], however, 
it is unknown whether sac/val can treat established DD 
in the setting of obesity. Furthermore, the immunologi-
cal responses to sac/val have not been extensively investi-
gated in these models.
Insulin resistant Zucker Obese (ZO) rats with estab-
lished DD are extensively used as a genetic model for 
diet-induced obesity. A leptin receptor mutation in the 
ZO rat prevents hypothalamic binding of leptin resulting 
in hyperphagia leading to severe obesity and progression 
to early-stage type 2 diabetes. Moreover, the develop-
ment of DD with insulin resistance at an early age in ZO 
rats also mimics the DD seen in obese young adolescents 
[3]. We have previously utilized ZO rats to elucidate the 
cellular and molecular mechanisms underlying reversal 
of obesity-associated DD by several therapeutics, includ-
ing a beta blocker [23], a Dipeptidyl peptidase-4 (DPP-
4) inhibitor, and a mineralocorticoid receptor blocker 
[24, 25]. Recently, we reported the beneficial effects of 
the combination of sac/val (LCZ696) in the treatment of 
early kidney injury in ZO rats [16]. In the present inves-
tigation, we investigated whether a ten-week treatment 
with sac/val could ameliorate progression of an already 
established abnormal cardiac phenotype in ZO rats. 
Moreover, we evaluated the efficacy of sac/val relative to 
val monotherapy. We have also analyzed changes in mul-
tiple cytokines using a cytokine array to identify novel 
potential targets for precision-based therapy. Herein, we 
report that sac/val, used as a treatment strategy, reduced 
the severity of DD in obese prediabetic ZO rats, and this 
was associated with increased IL-4 levels.
Methods
Animals
Sixty-four male Zucker Obese (ZO) and six age-matched 
Zucker Lean (ZL) rats were purchased from Charles 
River Laboratories (Wilmington, MA), and housed in a 
12  h light/dark cycled room. Animals were cared for in 
accordance with the National Institutes of Health guide-
lines. All procedures were approved and performed in 
but not val, increased IL‑4, which is increasingly recognized for its cardiovascular protection, possibly contributing, in 
part, to more favorable effects of sac/val over val alone in improving obesity‑associated DD.
Conclusions: These studies suggest that sac/val is superior to val in reversing obesity‑associated DD. It is an effec‑
tive drug combination to blunt progression of asymptomatic DD and vascular stiffness to HFpEF development in a 
preclinical model of obesity‑associated prediabetes.
Keywords: Obesity, Diabetes, Diastolic dysfunction, Neprilysin inhibition
Page 3 of 18Aroor et al. Cardiovasc Diabetol           (2021) 20:80  
accordance with the Subcommittee for Animal Safety at 
the Harry S Truman Veterans Memorial Hospital and 
the Institutional Animal Care and Use Committee of the 
University of Missouri. All ZO rats were weighed prior 
to the start of the experiment and randomly distrib-
uted into four treatment groups so that each group had 
a similar mean body weight. Beginning at 16  weeks of 
age, ZO rats received sac/val (ZOSV; 68 mg•kg−1•day−1), 
val (ZOV; 31  mg•kg−1•day−1), hydralazine (ZOH; 
30  mg•kg−1•day−1) or saline (ZOC) once daily for 
10 weeks by gavage. Rats were gavaged at a similar time 
each morning (6:00–7:00 am central standard time). 
Guidelines for dosing rats with sac/val and val were pro-
vided by Novartis (document #RD-2016-00069). Further, 
we determined that 30  mg/kg/day hydralazine was the 
most appropriate dose based on a preliminary telemetric 
BP study evaluating BP responses to 10 and 30  mg/kg/
day doses. In a recent report, we also reported the use 
of these drugs at a similar dose [16]. Body weights were 
measured weekly thereafter until the end of the experi-
ment (26 weeks of age). Untreated age-matched male ZL 
rats served as lean controls (ZLC). Six rats were removed 
from the study due to complications associated with oral 
gavage. Following sacrifice epidydimal and retroperito-
neal fat pad masses were excised and weighed and results 
were reported previously [16].
Telemetric blood pressure monitoring
Under isoflurane anesthesia (2% isoflurane in a stream 
of  O2), a subset of 13  week-old ZO rats (n = 16) were 
implanted with an abdominal aorta catheter attached to 
a radio transmitter (TA11PA-C40; Data Sciences Interna-
tional, St Paul, Minnesota), as previously described [16, 
26]. After a 3 week recovery, both systolic (SBP) and dias-
tolic blood pressures (DBP) were monitored in 300 s bins 
every 15 min for two 12 h light and two 12 h dark cycles 
(sampling rate, 1000  Hz), and telemetry data were ana-
lyzed post hoc. Monitoring periods ended 2  days prior 
to and approximately 3, 5, 7 and 9 weeks after treatment 
began. One rat was removed from the study prior to the 
start of BP monitoring due to complications from trans-
mitter implantation surgery. We have previously reported 
mean arterial pressures in the same rats used in this 
study [16].
Ultrasound assessment of aortic and cardiac function
Doppler ultrasound (Vevo 2100, Fujifilms, Visualson-
ics, Toronto, ON, Canada) studies were performed at 
the Small Animal Ultrasound Imaging Center at the 
Harry S Truman VA Research Center on isoflurane-
anesthetized rats (1.75–2% in 100% oxygen stream) near 
study end utilizing an MS250 (13–24 MHz) echo probe. 
Rats were placed on a heated platform to maintain body 
temperature at 37  °C and heart rate of 400 to 450 bpm. 
In vivo aortic stiffness was evaluated by the transit time 
method to determine aortic pulse wave velocity (PWV), 
as previously described [27]. Briefly, PWV was calculated 
as the difference in arrival times of a Doppler pulse wave 
at two locations along the aorta at a fixed distance. Pulse 
wave arrival times are measured as the time from the 
peak of the ECG R-wave to the leading foot of the pulse 
wave at which time velocity begins to rise at the start of 
systole. The measured distance between the two loca-
tions along the aorta is divided by the difference in arrival 
times and is expressed in m/s. Velocity waveforms were 
acquired at the aortic arch followed immediately by meas-
urement at the distal descending aorta a known distance 
from the aortic arch. Next, two-dimensional echocardio-
grams were performed in the apical four chamber view. 
In pulse wave (PW) Doppler mode, peak early (E) and 
late (A) diastolic blood flow velocities were obtained at 
the level of the mitral inflow stream just proximal to the 
mitral leaflets. From the PW spectra we determined iso-
volumic relaxation time (IVRT), isovolumic contraction 
time (IVCT) and ejection times, parameters needed to 
calculate the myocardial performance index (MPI), also 
known as the Tei index. MPI was calculated as the sum 
of isovolumic contraction and relaxation times divided by 
ejection time. B- and M-mode images of the left ventricle 
and septum in short axis view were acquired at the level 
of the papillary muscles. Left ventricular anterior and 
posterior wall thicknesses at end systole (LVAWTs and 
LVPWTs) and diastole (LVAWTd and LVPWTd), lumi-
nal diameters (LVIDs and LVIDd) and ejection fraction 
(EF) were determined offline in M-mode. Next, Tissue 
Doppler Imaging (TDI) was performed in the apical four 
chamber view by placing a sample volume at the septal 
annulus to acquire early (e’) and late (a’) septal annular 
velocities. Using a modified parasternal long axis view of 
the left ventricle and aortic root we determined stroke 
volume (SV) and cardiac output (CO). A sample volume 
was placed in the aortic outflow tract to obtain blood 
velocity spectra in Doppler PW mode. Offline calculation 
of the velocity time integral of PW traces and measure-
ment of the maximum diameter of the ascending aorta 
acquired in B-mode were used to calculate SV and CO 
using onboard software. Parameters were assessed using 
an average of three heart beats from two to three differ-
ent spectra, and calculations were made in accordance 
with the American Society of Echocardiography guide-
lines as well as specific guidelines for rodent echocardi-
ography. All data were acquired and analyzed offline by 
a single blinded observer. Although we had previously 
reported an abnormal diastolic phenotype in young male 
ZO rats (24, 25 and 29), herein we performed cardiac 
ultrasound on ten randomly selected ZO rats prior to the 
Page 4 of 18Aroor et al. Cardiovasc Diabetol           (2021) 20:80 
beginning of the treatment period (15 weeks old) in order 
to determine whether these rats have an abnormal pre-
existing cardiac phenotype (Table 1).
Ex vivo aortic reactivity by wire myography
Vasomotor responses of aortae were examined as pre-
viously described [27, 28]. Briefly, a 2  mm segment of 
thoracic aorta, collected immediately after euthanasia, 
was placed in ice-cold physiological salt solution (PSS) 
containing (in mM): 119 NaCl, 4.7 KCl, 2.5 CaCl, 1.18 
 KH2PO4, 1.17  MgSO4, 0.027 EDTA, 5.5 glucose, and 25 
 NaHCO3, pH 7.4. Aortic contractile state was ascertained 
using 80  mM KCl. Initially, aortas were preconstricted 
with U46619 (100  nM), a thromboxane A2 mimetic. 
Relaxation responses of arterial rings to acetylcholine 
(1 nM to 100 μM) were assessed by cumulative addition 
of agonist to the vessel bath. At the end of each experi-
ment, the PSS bath solution was replaced with  Ca2+-free 
PSS to determine maximal passive diameter. Aortic 
dilator responses are presented as percent maximal 
relaxation.
Ex vivo endothelial cell (EC) stiffness by atomic force 
microscopy (AFM)
The stiffness of EC, measured as the force exerted by a 
stylus probe on the luminal surface of aortic explants, 
was measured by a nano-indentation technique utilizing 
AFM, as previously described by us [27]. Briefly, a 2 mm 
ring of the thoracic aorta was isolated from rats to assess 
the stiffness of EC. The aortic ring was opened longitu-
dinally, and the adventitial surface of each explant was 
fastened to a glass cover slip using Cell-Tak cell tissue 
adhesive so that we had en face access to the EC surface 
for placement of the AFM stylus. Stiffness of the EC sur-
face was estimated by placing the stylus at approximately 
15 random locations along the EC surface of an explant 
and determining the average EC stiffness for that aorta.
Quantification of myocardial interstitial and periarterial 
fibrosis
Two mm-thick slices of the LV free wall were fixed in 
paraformaldehyde, embedded in paraffin, sectioned at 
five microns and stained for collagens using Picro Sirius 
Red (PSR), as previously described [29]. For each animal, 
an average estimate of interstitial fibrosis was calculated 
from four randomly selected regions. Periarterial fibro-
sis was determined by normalizing the area of PSR stain 
surrounding an arteriole to arteriolar diameter (diam-
eter = circumference of artery/3.14). Average values for 
each animal were based on measurements made on four 
randomly selected coronary arterioles from ZLC (n = 6), 
ZOC (n = 5), ZOSV (n = 5), ZOV (n = 6) and ZOH 
(n = 7).
Analysis of cardiac and aortic 3‑nitrotyrosine (3NT)
We evaluated the levels of 3NT as a marker of myocar-
dial nitrosylated oxidation products caused by the forma-
tion of peroxynitrite. Five-micron sections of the LV free 
wall were initially quenched of endogenous peroxidase 
and incubated overnight with rabbit polyclonal anti-3NT 
antibody (1:200; Chemicon, Temecula, CA). Sections 
Table 1 Ultrasound derived cardiac function and structure 
parameters of Zucker Obese rats prior to the ten‑week treatment 
period (N = 10;  ZOC/pre) and following the ten‑week treatment 
period (N = 6;  ZOC/post)
Values are mean ± SE, (sample sizes shown in parentheses). *p < 0.05 vs  ZOC/pre. 
HW Heart weight, tibia length tibia length, LV left ventricle, e’ early septal wall 
velocity during diastole, a’ late septal wall velocity during diastole, s’ peak 
septal wall velocity during systole, E early mitral flow velocity, A late mitral flow 
velocity, E/E’ LV filling pressure, IVRT isovolumic relaxation time; IVCT isovolumic 
contraction time; MPI myocardial performance index, LVETI LV ejection time 
index, LA left atrium diameter, Ao aorta diameter, AWTd anterior wall thickness 
at end diastole; PWTd posterior wall thickness at end diastole, LVIDd LV inner 
diameter at end diastole, LVIDs LV inner diameter at end systole
Parameter sample size ZOC/pre (10) ZOC/post (6)
Body weight (g) 560 ± 7 752 ± 17*
Heart weight (mg) NA 1429 ± 62
HW/TL (mg  mm−1) NA 18.1 ± 0.5
Systolic parameters
 Ejection fraction (%) 82 ± 2 76 ± 2*
 Cardiac output (ml  min−1) 302 ± 56 270 ± 29
 Stroke volume (µl) 828 ± 164 762 ± 90
 IVCT (ms) 12.5 ± 0.9 15.5 ± 0.6
 s’ (mm  sec−1) 43 ± 1 42 ± 3
 Ejection time (ms) 65 ± 3 71 ± 2
 LVETI 695 ± 22 685 ± 17
 Systolic time (ms) 99 ± 3 112 ± 3*
Diastolic parameters
 E, (mm  sec−1) 921 ± 49 1117 ± 126
 A, (mm  sec−1) late 828 ± 60 1036 ± 127
 E/A ratio 1.06 ± 0.05 1.07 ± 0.08
 e’, (mm  sec−1) 36 ± 2 52 ± 6*
 a’, (mm  sec−1) 54 ± 5 69 ± 10
 e’/a’ ratio 0.69 ± 0.06 0.76 ± 0.05
 E/e’ (LV filling pressure) 24.5 ± 1.0 22.7 ± 2.6
 Diastolic stiffness (E/e’/LVIDd) 3.26 ± 0.10 2.68 ± 0.29
 IVRT (ms) 20.8 ± 0.9 25.8 ± 1.4*
 MPI 0.54 ± 0.04 0.58 ± 0.01
Structural parameters
 LA/Ao ratio 1.51 ± 0.06 1.38 ± 0.11
 LV Mass (mg) 926 ± 44 1067 ± 19*
 AWTd (mm) 2.12 ± 0.09 2.07 ± 0.05
 PWTd (mm) 1.87 ± 0.09 1.83 ± 0.11
 Relative wall thickness 0.53 ± 0.03 0.46 ± 0.03
 LVIDd (mm) 7.55 ± 0.11 8.45 ± 0.21*
 LVIDs (mm) 3.60 ± 0.16 4.44 ± 0.16*
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were washed and incubated with appropriate secondary 
antibody. Diaminobenzidine (DAB; DAKO) served as 
a chromogen. Using a 50i Nikon microscope, five ran-
domly selected 10X bright-field images from each sec-
tion were captured with a CoolSNAP cf camera. Signal 
intensities of brownish color, which is indicative of the 
3NT level, were quantified by MetaVue software. Aver-
age values for each group were based on measurements 
made on four randomly selected coronary arterioles from 
ZLC (n = 6), ZOC (n = 5), ZOSV (n = 5), ZOV (n = 6) and 
ZOH (n = 7).
Analysis of intracardiac cytokine protein profile 
by Quantibody® Rat Cytokine Array 65
Protein extraction from frozen heart samples was per-
formed by RayBiotech using a proprietary method 
(Peachtree Corners, GA). Changes in cytokine protein 
levels in the heart were custom analyzed by RayBiotech 
using a highly sensitive quantitative ELISA-based Rat 
Cytokine Array Q67 and evaluated using proprietary 
software. This array is a combination of 2 nonoverlapping 
arrays that facilitates quantitative measurement of the 
concentrations of 67 rat cytokines by using appropriate 
antibody pairs. Within the array, an individual cytokine 
was represented four times, along with positive and nega-
tive controls which allows for calculating standard devia-
tion. Differences in cytokine expression were expressed 
as  log2 fold changes. Unpaired two-tailed t-tests were 
used to determine the significance (p < 0.05) of differ-
entially expressed cytokines between different groups 
(e.g., ZOC versus ZOSV, ZOV or ZOH). Cytokines that 
exhibited statistically significant differences between the 
treatment and control groups were selected for input into 
Ingenuity Pathway Analysis (IPA, QIAGEN, German-
town, MD) to identify diseases and functions that were 
affected. Heatmaps were generated using the ggplot2 
package for R.
Statistical analysis
Results are reported as mean ± SE. One-way ANOVA 
and post hoc t-tests (Fisher’s LSD), or corresponding 
non-parametric Kruskal–Wallis (Dunn’s), as indicated, 
were performed to examine differences in outcomes 
between ZL rats and control and treated ZO groups. 
Alternatively, we performed two-tailed Student t-tests 
between two groups when ANOVA post hoc tests indi-
cated p = 0.10. A p value < 0.05 was considered sig-
nificant. Two-way ANOVA was used to compare aortic 
responses among groups to increasing concentrations of 
acetylcholine in the tissue bath (group x Ach concentra-
tion). Differences in systolic or diastolic blood pressure at 
the last measurement period following administration of 
sac/val, val or hydralazine versus untreated ZO rats were 
determined by Student t-tests adjusted by variance. Sam-
ple sizes are listed in tables and figures. The heatmaps 
were normalized by scaling the values using the sum of 
each row. The z-scores were calculated with the Creative 
Commons Attribution-ShareAlike 2.0 Generic from the 
University of Alberta, Canada.
Results
Blood pressure and baseline metabolic parameters
We have previously reported increases in body weight, 
fat pad mass, fasting glucose, HbA1c, fasting insulin and 
insulin resistance in ZOC rats and these parameters were 
unaltered by sac/val, val or hydralazine treatment [16]. 
The increased systolic and diastolic pressures observed 
in untreated ZO rats were significantly lowered in all the 
treatment groups (Fig. 1).
Structural remodeling and diastolic dysfunction
We have previously reported cardiac hypertrophy and 
DD in male ZO rats as young as nine weeks of age [23, 
24, 28]. Herein, we determined that 10 randomly selected 
ZOC exhibited cardiac hypertrophy and an abnormal 
diastolic phenotype prior to initiation of interventions 
(Table 1), indicating that the study is directed as a treat-
ment strategy rather than a prevention strategy.
At the end of the study period, untreated ZO rats 
(ZOC) exhibited cardiac hypertrophy evidenced by 
Fig. 1 Ambulatory blood pressure was monitored periodically 
utilizing radio‑telemetric transmitters. Systolic blood pressure (SBP) 
and diastolic blood pressure were recorded prior to the beginning 
of treatment and after 3, 5, 7 and 9 weeks of treatment during the 
light and dark cycles. SBP and DBP increased throughout the course 
of treatment in ZOC. After 9 weeks of treatment SBP and DBP were 
significantly reduced in ZOSV during the light and dark periods 
compared to ZOC (p < 0.05 indicated by the dagger (†) symbol). N = 4, 
4, 3 and 4 for ZOC, ZOSV, ZOV and ZOH, respectively
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increases in heart weight (HW) (25%), HW normalized 
to tibia length (HW/TL) (72%), left ventricular (LV) mass 
(24%), and anterior wall thickness at end diastole (AWTd) 
(29%) compared age-matched non-diabetic, Zucker Lean 
rats (ZLC) (Table 2). ZOC and ZLC exhibited EF ≥ 69% 
indicating normal systolic function. However, compared 
to ZLC, ZOC exhibited DD characterized by a decrease 
in the tissue Doppler derived e’/a’ ratio (38%), in concert 
with increases in LV filling pressure (E/e’ ratio, 220%), 
diastolic stiffness (E/e’/LVIDd, 230%), isovolumic relaxa-
tion time (IVRT, 47%) and the myocardial performance 
index (MPI, 23%). Collectively, these parameters dem-
onstrate abnormal LV wall motion during diastole (e’/a’ 
and E/e’), passive LV wall stiffness (E/e’/LVIDd) and 
prolongation of the active energy requiring period of 
relaxation (IVRT). Additionally, DD in ZOC was associ-
ated with left atrial remodeling indicated by an increase 
in the left atrial to aortic root (LA/Ao) ratio (45%), an 
effect that reflects the response by the thin-walled atrium 
to increased luminal pressure.
Although untreated ZO rats (ZOC) exhibited cardiac 
hypertrophy indicated by increases in HW, LV mass, 
and AWTd, these parameters were not altered by sac/
val (ZOSV), val alone (ZOV), or hydralazine (ZOH) 
(Table 2). However, a moderate, but significant, degree of 
fibrosis in the interstitial region was seen in ZOC com-
pared to ZLC (Fig. 2a). Though sac/val, val and hydrala-
zine were all effective in decreasing fibrosis in ZO rats, 
Table 2 Ultrasound derived cardiac function and structure parameters of lean and obese Zucker rats 
Values are mean ± SE, (sample sizes shown in parentheses). *p < 0.05 vs ZLC; †p < 0.05 vs ZOC; §p < 0.05 vs ZOH; ‡p < 0.05 vs ZOL. HW Heart weight, tibia length tibia 
length, LV left ventricle, e’ early septal wall velocity during diastole, a’ late septal wall velocity during diastole, s’ peak septal wall velocity during systole, E early mitral 
flow velocity, A late mitral flow velocity, E/E’ LV filling pressure, IVRT isovolumic relaxation time, IVCT isovolumic contraction time, MPI myocardial performance index, 
LVETI LV ejection time index, LA left atrium diameter, Ao aorta diameter, AWTd anterior wall thickness at end diastole, PWTd posterior wall thickness at end diastole, 
LVIDd LV inner diameter at end diastole, LVIDs LV inner diameter at end systole
Treatment ZLC ZOC ZOSV ZOV ZOH
(6) (10) (11) (11) (10)
Heart weight (mg) 1147 ± 41 1429 ± 62* 1392 ± 67*§ 1302 ± 35*§ 1639 ± 50*
HW/TL (mg  mm−1) 10.5 ± 0.3 18.1 ± 0.5* 16.8 ± 0.7*§ 17.3 ± 0.4§ 15.8 ± 0.6*
Systolic parameters (6) (6) (6) (7) (6)
 Ejection fraction (%) 69 ± 3 76 ± 2 81 ± 2* 80 ± 2* 80 ± 4*
 Cardiac output (ml  min−1) 190 ± 23 270 ± 29 281 ± 24* 260 ±  19§ 342 ± 36*
 Stroke volume (µl) 504 ± 52 762 ± 90 828 ± 74* 768 ± 54 874 ± 111*
 IVCT (ms) 12.5 ± 0.9 15.5 ± 0.6 11.7 ± 1.3† 13.7 ± 1.9 13.5 ± 2.9
 s’ (mm  sec−1) 58 ± 1 42 ± 3* 41 ± 1* 43 ± 3* 48 ± 6
Diastolic parameters (6) (6) (6) (7) (6)
 E, (mm  sec−1) 888 ± 56 1117 ± 126 894 ± 53 1095 ± 63 1091 ± 60
 A, (mm  sec−1) late 886 ± 36 1036 ± 127 814 ± 70 973 ± 54 1098 ± 127
 E/A ratio 1.00 ± 0.04 1.07 ± 0.08 1.12 ± 0.06 1.15 ± 0.11 1.03 ± 0.11
 e’, (mm  sec−1) 94 ± 7 52 ± 6* 55 ± 7* 56 ± 8* 76 ± 10
 a’, (mm  sec−1) 76 ± 4 69 ± 10 51 ± 3*§ 76 ±  6‡ 68 ±  4‡
 e’/a’ ratio 1.23 ± 0.03 0.76 ± 0.05* 1.08 ± 0.12† 0.75 ± 0.08*‡§ 1.12 ± 0.13†
 E/e’ (LV filling pressure) 10.3 ± 0.7 22.7 ± 2.6* 17.1 ± 1.5 20.9 ± 2.4* 15.5 ± 2.6
 Diastolic stiffness (E/e’/LVIDd) 1.16 ± 0.13 2.68 ± 0.29* 2.09 ± 0.22* 2.51 ± 0.30*§ 1.67 ± 0.25†
 IVRT (ms) 17.5 ± 0.7 25.8 ± 1.4* 21.3 ± 0.7*† 20.3 ± 0.6*† 18.4 ± 1.8†
 Ejection Time (ms) 64.7 ± 2.4 71.1 ± 1.7 68.4 ± 1.8 66.5 ± 3.1 60.4 ± 2.0
 LVETI 702 ± 13 685 ± 17 650 ± 12* 716 ± 32 679 ± 27
 MPI 0.47 ± 0.03 0.58 ± 0.01* 0.49 ± 0.03† 0.52 ± 0.04 0.52 ± 0.06
Structural parameters (6) (6) (6) (7) (6)
 LA/Ao ratio 0.95 ± 0.05 1.38 ± 0.11* 1.23 ± 0.10* 1.28 ± 0.03* 1.35 ± 0.05*
 LV Mass (mg) 863 ± 35 1067 ± 19* 1104 ± 73*§ 976 ±  45§ 1340 ± 64*†
 AWTd (mm) 1.60 ± 0.07 2.07 ± 0.05* 2.07 ± 0.16* 1.87 ± 0.07 2.03 ± 0.08*
 PWTd (mm) 1.68 ± 0.06 1.83 ± 0.11 2.04 ± 0.16* 1.81 ± 0.10 2.08 ± 0.05*
 Relative wall thickness 0.38 ± 0.02 0.46 ± 0.03* 0.50 ± 0.04* 0.44 ± 0.02* 0.45 ± 0.02*
 LVIDd (mm) 8.71 ± 0.25 8.45 ± 0.21 8.26 ± 0.17§ 8.32 ± 0.14§ 9.22 ± 0.26†
 LVIDs (mm) 5.24 ± 0.29 4.44 ± 0.16* 3.99 ± 0.26* 4.09 ± 0.23* 4.55 ± 0.47
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the magnitude of decease was not different between the 
three treated groups. The extent of fibrosis in periarte-
rial region was increased in ZOC rats (Fig. 2b) and was 
decreased significantly in ZOSV and ZOV, but not in 
ZOH.
The comparison of different parameters of DD in 
ZOC and the treated groups is summarized in Table 2. 
Compared to ZOC, the e’/a’ ratio improved by 42% in 
ZOSV and 47% in ZOH, but not in ZOV (-1%). Indeed, 
ZOV was significantly lower than in ZOC, ZOL and 
ZOH. Compared to ZOC, LV filling pressure (E/e’) 
was lower by 25, 8 and 32% in ZOSV, ZOV and ZOH, 
respectively, although the differences were not signifi-
cant. Similarly, compared to ZOC, diastolic stiffness 
index (E/e’/LVID) was lower by 22, 6 and 38% in ZOSV, 
ZOV and ZOH, respectively. IVRT was significantly 
reduced (improved) by 17, 21 and 29% in ZOSV, ZOV 
and ZOH, respectively, compared to ZOC. MPI, which 
is an index of global cardiac function (i.e., diastolic and 
systolic), was improved by 16, 10 and 10% in ZOSV, 
ZOV and ZOH, respectively, however only ZOSV 
was significantly lower than ZOC. Sac/val tended to 
improve diastolic stiffness index and improved e’/a’ 
(p < 0.05) ratio compared to val. Although hydralazine 
is as effective as sac/val at improving DD parameters, it 
Fig. 2 Sacubitril/valsartan (sac/val) reduces left ventricular myocardial interstitial (a) and periarterial (b) fibrosis in ZO rats. Representative PSR 
stained images show fibrosis in the myocardial interstitium (a) or surrounding an arteriole (b). Accompanying bar graphs show quantitative analysis 
of average intensity of PSR staining in panel a and area of fibrosis normalized to arteriole diameter in panel b. Data are represented by means ± SE. 
N = 6, 6, 5, 5 and 7 for ZOC, ZOSV, ZOV and ZOH, respectively. Symbols: *Indicates p < 0.05 versus ZLC; †Indicates p < 0.05 versus ZOC. Scale 
bars = 50 µm
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causes significant increase in LVMI which is considered 
to contribute to progression of cardiac dysfunction.
Oxidative stress
Oxidative stress is an important determinant that either 
precedes or is associated with the development of DD in 
rodent models of obesity-associated cardiomyopathy [26, 
30]. We have evaluated oxidative stress by analyzing the 
extent of 3-nitrotyrosine (3NT) accumulation in both 
interstitial and periarterial regions in the heart. Accu-
mulation of 3NT in interstitium is increased in untreated 
ZO rats (p < 0.05 vs ZLC), but decreased in all three treat-
ment groups (Fig. 3a) (p < 0.05 versus ZOC). In contrast 
to interstitial 3NT accumulation, periarterial 3NT was 
marginally increased in ZO rats compared to control 
ZLC rats (p = 0.06), and neither sac/val, val or hydrala-
zine had a significant effect on periarterial nitroso-oxida-
tive stress (Fig. 3b).
Aortic stiffness and relaxation
We have determined aortic compliance by measur-
ing in  vivo pulse wave velocity (PWV) and ex  vivo aor-
tic stiffness by atomic force microscopy (AFM) in 
aortic explants. Compared to untreated ZO rats, PWV 
was decreased similarly in all three treatment groups 
(p < 0.05) (Fig.  4a). Endothelial cell surface stiffness was 
also significantly decreased in ZOSV, ZOV and ZOH 
groups compared to the ZOC group (Fig. 4b). We further 
Fig. 3 Sacubitril/valsartan (sac/val) reduces myocardial interstitial (a) and periarterial (b) nitroso‑ oxidative stress in ZO rats. Representative images 
of 3‑nitrotyrosine immunostaining as a marker for nitroso‑oxidative stress with accompanying bar graphs showing quantitation of measures of 
intensity. Data are represented by means ± SE. N = 5, 5, 5, 5 and 5 for ZOC, ZOSV, ZOV and ZOH, respectively. Symbols: *Indicates p < 0.05 versus ZLC; 
†Indicates p < 0.05 versus ZOC
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examined endothelial dependent aortic relaxation. We 
previously reported impaired endothelium-dependent 
vasodilation in younger and older ZO rats [24, 26]. We 
anticipated impaired endothelium-dependent vasodila-
tory responses to acetylcholine and insulin in the aorta of 
ZOC and improvement with sac/val, to a greater extent 
than to val or hydralazine. As expected, acetylcholine-
induced vasodilation was significantly lower in ZOC 
relative to ZLC (Fig.  4c). However, treatment with sac/
val or val, but not hydralazine, showed normal responses 
to acetylcholine, and are similar to ZLC. Responses to 
insulin and the endothelium-independent vasodila-
tor, sodium nitroprusside were not different among the 
groups tested (not shown).
Cytokine measurements
To explore the molecular mechanisms in the ZLC, ZOC, 
ZOSV, and ZOV groups (N = 4 in each group) that could 
potentially mediate the functional/structural changes in 
the heart, we used a commercial service to measure 67 
cytokines using a Cytokine Array. Given the exploratory 
nature of these experiments and the small sample size, 
we did not adjust the significance values for multiple test-
ing and p-value ≤ 0.05 was considered significant. We 
found that five cytokines, namely RANTES, PDGF-AA, 
GFR-alpha-1, SCF, and IL-7, were differentially expressed 
between the lean (ZLC) and obese (ZOC) rats (Table 3). 
Relative to the ZOC rats, the ZOV rats showed downreg-
ulation of five proteins, namely, Neuropilin-1, Notch-1, 
JAM-A, RANTES, and Flt-3L (Table 4). Remarkably, the 
ZOSV rats showed reduced expression of Neuropilin-1, 
Notch-1, and JAM-A relative to ZOC rats which was 
similar to that seen in ZOV rats (Table 4). In addition, the 
ZOSV rats showed increased expression of PDGF-AA, 
L-Selectin, IFN-γ, and IL-4 when compared to the ZOC 
rats. A heatmap of the relative differences of statistically 
significant cytokines in cardiac lysates across the ZOC, 
ZOV, and ZOSV rats is shown in Fig.  5. The increased 
expression of the aforementioned four proteins distin-
guishes ZOSV rats from ZOV rats suggesting that they 
could potentially mediate the effects associated with sac/
val treatment.
Fig. 4 Sacubitril/valsartan (sac/val) ameliorates in vivo aortic stiffening, as well as endothelial stiffening in ex vivo aortic explants. a Pulse wave 
velocity (PWV) measured after 10 weeks of treatment. N = 6, 5, 5, and 7 for ZOC, ZOSV, ZOV and ZOH, respectively. b Force measurements were 
acquired by interaction between a cantilever tip and the EC surface of aortic explants from rats after 10 weeks of treatment. N = 4, 4, 4, 5 and 
3 for ZOC, ZOSV, ZOV and ZOH, respectively. c Sac/val (▼) and val (○) treatments prevent impaired responses to the nitric oxide dependent 
vasodilator, acetylcholine in aortic rings of ZO rats (○). Note the normal reactivity of in ZLC aortae (●). Data are represented by means ± SE in the 
accompanying bar graph. N = 3, 8, 8, 7 and 7 for ZLC, ZOC, ZOSV, ZOV and ZOH, respectively. Symbols: *Indicates p < 0.05 versus ZLC; †Indicates 
p < 0.05 versus ZOC; indicates §p < 0.05 versus ZOH
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IPA analysis
We then sought to map the differentially expressed 
cytokines detected in the ZOL rats to the networks that 
may mediate the effects of sac/val that are accessible 
through the Ingenuity database. We did not perform a 
similar analysis for the ZOV rats as only five cytokines 
were differentially expressed in these rats relative to ZOC 
and three of them were also present in the ZOL rats. Our 
analysis generated a single network with a score of 21 
with the following associated functions: cellular devel-
opment, cellular movement, cellular growth, and pro-
liferation (Fig.  6). The network included the following 
focus (experimentally detected) molecules: NOTCH-1, 
IL-4, IFN-γ, PDGFA, F11R, L-Selectin (SELL), and NRP1. 
Remarkably, one of the focus molecules of the network 
is Notch-1, a key player in vascular remodeling and 
endothelial and SMC communication. The cellular and 
molecular functions of the molecules in the network were 
related to cell morphology, cell movement, cell death and 
survival. cell-to-cell signaling and interaction, and cellu-
lar development. The top disease and functional anno-
tation of these molecules is the inflammatory response 
(P = 2.54E−04–1.79E−10) and are related to macrophage 
polarization (P = 1.79 E−10) and leukocyte emigra-
tion (P = 1.07E−9). Of note, mapping these molecules 
to clinical pathology endpoints suggested an association 
with cardiac enlargement (P = 6.41E−02–6.20E−05). 
The top canonical pathways predicted were the Th1 
(P = 5.07E−06) and Th2 pathways (P = 7.20E−06). Nota-
bly, IL-4 that anchors Th2 pathway plays a key role in 
macrophage polarization that is important in vascular 
remodeling.
Discussion
In the present investigation, we determined the poten-
tial therapeutic effects of sacubitril/valsartan (sac/val; 
LCZ696), a combination of Ang II receptor blocker and 
neprilysin (NEP) inhibitor (ARNi), on cardiovascular 
remodeling and function in pre-diabetic obese rats. We 
then compared the effects of dual blockade (sac/val) with 
val monotherapy, and to those of hydralazine, a blood 
pressure lowering drug, to determine the cardiovascu-
lar protection. Furthermore, we performed cytokine 
array analysis of selected proteins showing differences 
in distinct signaling pathways. For the first time, we have 
Table 3 Summary of cytokine profile changes in Zucker Obese 
(ZOC) rats when compared to control Zucker Lean rats (ZLC)
RANTES Regulated upon Activation, Normal T Cell Expressed and Presumably 
Secreted, PDGF Platelet Derived Growth Factor, GFR-alpha-1 Glial Cell 
line-derived Neurotrophic Factor Receptor Alpha 1, SCF Stem Cell Factor, IL 
Interleukin
Molecules on the cytokine array that showed at least  log2 fold-change  (log2FC) 
of 1.2 and with a p-value ≤ 0.05 are shown. Statistical significance between the 
indicated groups determined by unpaired two-tailed t-tests. Gene symbols 
corresponding to each cytokine are shown. Sample size: N = 4/group
Molecule Gene ZOC/ZLC
log2FC P‑value
RANTES Ccl5 − 1.288 0.050
PDGF‑AA Pdgfa − 1.359 0.012
GFR‑alpha‑1 Gfra1 − 0.885 0.049
SCF Kitl − 0.269 0.043
IL‑7 Il7 − 0.655 0.024
Table 4 Summary of cytokine profile changes in Zucker Obese (ZO) rats treated with sacubitril/valsartan (ZOSV), valsartan (ZOV), and 
hydralazine (ZOH) when compared to control rats (ZOC)
Notch Notch receptor 1, IFN Interferon, JAM-A Junctional Adhesion Molecule A, Flt-3L FMS related Receptor Tyrosine Kinase 3 Ligand
Molecules on the cytokine array that showed at least  log2 fold-change  (log2FC) of 1.2 and with a p-value ≤ 0.05 are shown. Statistical significance between the 
indicated groups determined by unpaired two-tailed t-tests. Gene symbols corresponding to each cytokine are shown. Sample size: N = 4/group
Molecule Gene ZOSV /ZOC ZOV/ZOC ZOH/ZOC
log2FC P‑value log2FC P‑value log2FC P‑value
Neuropilin‑1 Nrp1 − 0.266 0.001 − 0.398 0.005 − 0.173 0.052
Notch1 Notch1 − 0.768 0.003 − 1.108 0.002 − 0.976 0.002
PDGF‑AA Pdgfa 1.054 0.041
L‑Selectin Sell 0.800 0.044
IFNg Ifng 0.550 0.020
IL‑4 Il4 0.386 2.61E‑05
JAM‑A F11r ‑− 0.271 0.021 − 0.317 0.010
RANTES Ccl5 − 0.436 0.014
Flt‑3L Flt3l − 0.464 0.047
IL‑17F Il17f − 0.668 0.037
Galectin‑3 Lgals3 − 0.572 0.044
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shown the enhanced cardiovascular protection afforded 
by sac/val on selective parameters of diastolic dysfunc-
tion, as well systolic dysfunction, and large artery stiff-
ness compared to val and hydralazine.
Diastolic dysfunction (DD), characterized by 
impaired relaxation of the left ventricle, is one of the 
early manifestations of heart failure with preserved 
ejection fraction (HFpEF) [31, 32]. Childhood-adoles-
cent overweight and obesity are major health burdens 
around the globe and the presence of DD has signifi-
cant impact as a risk factor for the progression of CVD 
[4, 5]. However, drugs targeting systolic dysfunction are 
not usually considered as effective in the management 
of DD, thereby necessitating the need to develop drugs 
that specifically target DD, especially in the setting of 
obesity [33, 34]. In this regard, obesity-induced DD 
is associated with multiple abnormalities, including 
inappropriate activation of tissue Renin–Angioten-
sin–Aldosterone System (RAAS) [24, 35, 36], as well 
as, normal or subnormal responses to ANP in the early 
stages of the disease or enhanced ANP responsiveness 
at later stages [17]. Sac/val is a first-in-class approved 
ARNi, that simultaneously provides Ang II type I 
receptor blockade and NP inhibition. Cardiac protec-
tion afforded by sac/val is well recognized with comple-
tion of first and second phase clinical trials [37–41]. A 
Fig. 5 Heatmap illustrating differential cytokine expression in ZOC, ZOV and ZOSV rat cardiac lysates (N = 4 per group). Individual samples are 
shown on the x‑axis. The y‑axis shows statistically significant (P ≤ 0.05), differentially expressed cytokine markers among the three groups. Each 
row in the heatmap represents relative changes in the normalized protein expression in the control and treated rats. Need acronyms for cytokines. 
SCF stem cell factor, IFN-γ interferon gamma, JAM.A junctional adhesion molecule‑A, RANTES regulated on activation, normal T cell expressed and 
secreted, Flt.3L Fms‑like tyrosine kinase 3 ligand; GFR‑alpha‑1, PDGF-A platelet derived growth factor‑A
Page 12 of 18Aroor et al. Cardiovasc Diabetol           (2021) 20:80 
recent study also favored the beneficial effects of sac/
val in HFpEF patients [42]. Therefore, we have chosen 
Zucker Obese rats, a preclinical model of early DD, to 
represent young patients with cardiometabolic syn-
drome with a constellation of features, including hyper-
tension, hyperlipidemia and insulin resistance [43]. We 
then compared the efficacy of sac/val with val alone and 
with hydralazine, a blood pressure lowering agent.
All three drugs, sac/val, val and hydralazine, improved 
IVRT, a parameter of prolongation of the active energy 
phase of relaxation. However, impairment in LV wall 
motion during diastole, observed in untreated ZOC 
rats and indicated by an increase in the e’/a’ ratio, was 
improved by sac/val, but not val. Moreover, sac/val, but 
not val, tended to improve passive LV wall stiffness (E/e’/
LVIDd). MPI (Myocardial Performance Index), which 
Fig. 6 Network created by Ingenuity Pathway Analysis from the ZOSV rats. The network was generated from differentially expressed proteins when 
compared to ZOC rats (N = 4 per group). The list was selected based on the proteins meeting the threshold of  log2FC of 1.2 and p‑value ≤ 0.05. 
Colored nodes represent the genes derived from our uploaded protein list (focus genes) with green nodes representing downregulation and red 
nodes representing upregulation. White nodes represent genes or molecules that could potentially be connected to the focus genes and are 
derived from the IPA knowledge base. The solid lines represent direct interactions between the nodes. A detailed explanation of the molecule 
shapes is  available at http:// qiagen. force. com/ Knowl edgeB ase/ artic les/ Basic_ Techn ical_Q_ A/ Legend
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is an index of global cardiac function (i.e., diastolic and 
systolic), was significantly improved only by sac/val, 
potentially due in part to improvement in IVCT. Taken 
together, sac/val treatment appears to be superior in 
improving DD in this preclinical model of obesity car-
diomyopathy. Interestingly, the enhanced efficacy of sac/
val occurred without significant improvement in blood 
glucose or insulin levels and suggests that these benefits 
occur independent of glycemic control.
The factors contributing to HFpEF in contrast to 
HFrEF have been diverse, including endothelial dysfunc-
tion, changes in intrinsic cardiomyocyte stiffness with 
relaxation abnormalities, LV hypertrophy, and low-grade 
metabolic inflammation with variable extent of fibrosis 
and oxidative stress [44–47]. Moreover, both associa-
tion and dissociation of Ang II and the NP system with 
markers of oxidative stress, blood pressure, maladaptive 
immune and inflammatory response, cardiac hypertro-
phy and fibrosis have all been reported in the context of 
preclinical DD and HF resulting from mechanical over-
load, genetic models of leptin resistance, and inappro-
priate activation of the RAAS [22, 24, 48–50]. Cardiac 
fibrosis, intrinsic stiffness and hypertrophy have all been 
shown to be caused, in part, by enhanced ROS generation 
in the cardiovascular tissue [9, 51, 52]. In fact, we have 
examined all of these components in the present study. 
Although we found suppression of ROS (3-NT) in LV 
interstitium by all three drugs to a similar extent, sug-
gesting that suppression of oxidative stress may, in part, 
contribute to improvement in DD, and the beneficial 
effects of sac/val may be mediated by factors independ-
ent of ROS accumulation.
Recent advances in gene expression and multiplexed 
protein arrays are increasingly used to understand the 
molecular pathophysiology of DD and HF in human and 
animal models of obesity, diabetes, pressure overload 
and myocardial infarction [53–55]. In the ZO heart tis-
sue the increases in cytokines, such as IL-6 and TNF-α 
are only marginally increased [56]. In the mouse model 
of diet-induced obesity (DIO), IL-6 levels are either not 
significantly altered or increased significantly depending 
on the dietary components [57, 58]. However, in a recent 
study investigating the effect of sac/val in a DIO model, 
the impact of this drug combination on cytokines was 
not investigated [22]. Therefore, we analyzed changes 
in multiple cytokines using a cytokine array. In the cur-
rent investigation, the array analysis revealed, among 
other things, that Notch-1 is markedly decreased by 
both sac/val and val. However, it appears that the effects 
of Notch-1 are cell type-specific. For example, Notch-1 
exerts protective effects in endothelial cells and car-
diomyocytes, but plays a deleterious role in fibroblasts 
and immune cells [59, 60]. Interestingly, both ZOSV 
and ZOV showed improvement in DD and suppressed 
Notch-1 expression, suggesting that the beneficial effects 
of sac/val and val in the ZO model of obesity-associated 
DD may be, in part, explained by suppression of Notch-1 
in fibroblasts and immune cells. However, ZOSV showed 
increased expression of IFN-γ compared to the other 
groups. Although IFN-γ is implicated in immune and 
inflammatory responses as a component of the Th1 
response, its increased expression has been shown to 
exert contrasting effects; promote cardiovascular dys-
function or mediate cardioprotective effects [61–66]. 
However, unlike in other studies [62–66], changes in 
IFN-γ levels did not correlate with suppression of cardiac 
hypertrophy in the sac/val-treated ZO rats.
IL-4 levels were also elevated in ZOSV, but not in ZOV, 
suggesting that increased IL-4 levels in this treated group 
might have contributed to the higher impact of sac/val 
over val in ZO rats. In fact, IL-4 is emerging as a cardio-
protective and repurposing molecule to improve cardiac 
dysfunction [67, 68]. IL-4 signals via IL-4Rα/IL-13Rα1, a 
hybrid receptor used by both IL-4 and IL-13. It is note-
worthy that the expression of this hybrid receptor is 
impaired in HF patients [69, 70]. Although IL-4 does 
not suppress cardiac fibrosis, it enhances cardiac func-
tion by improving cardiac metabolic functions possibly 
through signaling via this hybrid receptor to promote 
M2 macrophage polarization and suppression of cardiac 
inflammatory response [67–70]. Therefore, it is plausible 
that upregulation in IL-4 signaling in the sac/val treated 
ZO rats might have contributed to further improve-
ments in DD compared to val alone. The cytokine array 
also revealed that RANTES expression is suppressed in 
untreated and all treated groups, and more so in the ZOV 
group. In this regard, hyperinsulinemia as seen in ZO 
rats might have contributed to suppression of RANTES, 
although its role in DD is not fully understood [71, 72]. 
However, a limitation of our cross-sectional study design 
is that it does not capture the dynamic changes in the 
cytokine profile over the treatment period. In the future, 
we will include a longitudinal study design to gain further 
mechanistic insights into the beneficial effects of sac/val 
treatment.
Two critical determinants of cardiovascular protection 
are bioavailable nitric oxide and cyclic GMP [73]. While 
Ang II could decrease bioavailable nitric oxide by caus-
ing insulin-mediated impairment of eNOS activation 
and nitric oxide destruction, an increase in cyclic GMP 
by ANP will further enhance accumulation of cyclic 
GMP with a concomitant increase in nitric oxide produc-
tion and signaling [57]. Therefore, additional provision 
of cyclic GMP by sac/val compared to val alone might 
have contributed to further improvements in diastolic 
function observed in this study. Additional risk factors 
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like hypertension and myocardial hypertrophy also con-
tribute to DD. Surprisingly, all three drugs decreased 
blood pressure to a similar extent. The superior cardio-
protective effects afforded by sac/val compared to val 
in improving DD, despite similar BP responses in the 
two groups, suggests there may be a BP independent 
component to improvement in DD with the addition of 
sacubitril. Moreover, we did not find improvements in 
structural abnormalities, including cardiac hypertrophy, 
by sac/val or val, suggesting further that improvement 
in diastolic function occurs independent of improve-
ments in structural remodeling. In fact, improvement in 
diastolic function, independent of changes in blood pres-
sure, hypertrophy and structural remodeling, has been 
reported in both preclinical models of obesity cardiomy-
opathy and human patients [26, 74].
Obesity and diabetes affect the cardiovascular system 
by indirect and direct mechanisms involving both vascu-
lar and myocardial disorders, respectively. In this regard, 
improvement in aortic stiffness is often associated with 
better vascular health, and in turn diastolic function. 
Sac/val (ARNi) therapy has recently been shown to 
improve aortic compliance in HF patients [75]. In con-
cordance, our results also show that sac/val significantly 
improved aortic compliance by decreasing aortic stiff-
ness, as evaluated by PWV. Although arterial stiffness 
increases naturally with aging, the process is accelerated 
and occurs prematurely in the setting of obesity, insu-
lin resistance and diabetes [7]. Increased systolic pres-
sure and decreased diastolic pressure result in increased 
pulse pressure caused by stiffening of central arteries. An 
increase in systolic pressure causes an increase in car-
diac afterload, left ventricular mass, and oxygen demand, 
whereas decreased diastolic pressure impairs coronary 
blood flow. These changes can result in left ventricular 
remodeling, ischemia and fibrosis, all of which contrib-
ute to left ventricular diastolic dysfunction and coronary 
heart disease [7].
We used acetylcholine-dependent aortic relaxation as 
a surrogate for nitric oxide-dependent endothelial func-
tion. We observed improved acetylcholine-dependent 
vasorelaxation by sac/val and val. However, no such 
improvement was seen with hydralazine. PWV and 
endothelial surface stiffness measure overall stiffness 
of the vascular wall of aorta which was decreased by 
hydralazine, suggesting dissociation between vascular 
stiffness and nitric oxide-dependent vasodilatation. We 
have previously reported impaired microvascular remod-
eling as shown by increased Renal Resistivity Index (RRI) 
and renovascular fibrosis by hydralazine, but not sac/
val and val [16]. In this study, we also observed perivas-
cular fibrosis in the hydralazine treated ZO rats along 
with enhanced LV mass suggesting increased strain on 
the part of ventricles, in part, due to microvascular stiff-
ening by hydralazine. In this regard, it is noteworthy 
that although hydralazine is used in the management of 
hypertension, it is also known to suppress acetylcholine-
induced vasorelaxation, as observed in the present study 
[76].
Our study has some limitations. First, we have not 
measured cardiac or systemic ANP or BNP levels. In this 
regard, increased levels of NPs have been reported in 
symptomatic HF subjects, and are considered an indica-
tion of myocardial response to hemodynamic alterations 
or impaired responsiveness to the effects of NP due to 
counter regulatory signaling pathways [77–79]. In con-
trast, NP levels are often lower in the setting of obesity 
due to either impaired NP production or its enhanced 
degradation [80, 81]. Second, we used ZO rats that are 
considered somewhat older (26 weeks) compared to the 
studies performed in younger animals. However, we have 
evaluated renal protection by these three drugs in a com-
panion paper [16] and renal injury is usually manifested a 
few weeks later than the earliest manifestation of DD in 
these ZO rats [56, 82].
Conclusion
The prognosis of patients diagnosed with heart failure 
with preserved ejection fraction (HFpEF) remains poor, 
specifically in patients with comorbid conditions like 
obesity and diabetes. Further, there are no evidence-
based therapies to treat HFpEF. Therefore, therapeutic 
strategies are urgently needed to improve cardiovascu-
lar outcomes in subjects with HFpEF, including dias-
tolic dysfunction [10]. Using a preclinical model of 
obesity and pre-diabetes, here we report that sacu-
bitril/valsartan (sac/val; LCZ696), a combination of 
Ang II receptor blocker and neprilysin (NEP) inhibi-
tor (ARNi), improved echocardiographic parameters 
of ventricular stiffness that were impaired in untreated 
ZO rats. Moreover, sac/val was more effective at ame-
liorating diastolic dysfunction compared to val alone. 
Sac/val also blunted elevated vascular stiffness in ZO 
rats more effectively than val monotherapy. Although 
the antihypertensive drug hydralazine was as effective 
as sac/val in improving parameters of diastolic func-
tion, it failed to affect periarterial fibrosis and aortic 
compliance. While the immune suppressive effects of 
sac/val treatment are well recognized, our cytokine 
array analysis also suggests that this drug combina-
tion can have protective effects on DD through a pre-
viously unrecognized effect on IL-4 induction (Fig.  7). 
Thus, sac/val treatment may contribute to improve-
ment in cardiovascular stiffness through both common 
and novel pathways involving immune suppression and 
tissue repair. Our results also show that the sac/val 
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Fig. 7 Schematic showing the potential beneficial effects of sacubitril/valsartan combination in a genetic model of obesity and early diabetes 
with established diastolic dysfunction. The prodrug sacubitril is converted to sacubitrilat (LBQ657) in vivo via de‑ethylation by esterases, and is a 
known inhibitor of neprilysin and ANP and BNP degradation (1). By enhancing ANP and BNP levels and subsequent conversion of GTP to cGMP 
(2), sacubitrilat improves vasorelaxation and vascular regeneration and decreases RAAS/sympathetic tone and Notch1‑dependent inflammatory 
signaling (3). Additional enhancement of IL‑4 receptor signaling by sacubitrilat (4), but not valsartan, suppresses macrophage‑mediated 
inflammatory responses and enhances metabolic functions in cardiomyocytes through an IL‑4/IL‑13 hybrid receptor (5). Valsartan, on the 
other hand, blocks AT1R, and decreases aldosterone levels and MR signaling (6), resulting in improved vascular relaxation and decreased RAAS, 
sympathetic tone and Notch1‑dependent inflammatory responses (7). Collectively, this drug combination reduces diastolic dysfunction (8) and 
vascular stiffness (9) by reducing aortic stiffness, oxidative stress, inflammatory responses, and cardiac fibrosis (10 and 11) by modulating ANP/BNP, 
AT1R, MR and IL‑4/IL‑13 mediated signaling in a genetic model of obesity and early diabetes. ANP, Atrial Natriuretic Peptide; AngII, Angiotensin II; 
Aldo, Aldosterone; BNP, Brain Type Natriuretic peptide; AT1R, Angiotensin type 1 Receptor; MR, Mineralocorticoid Receptor; IL‑4, Interleukin‑4; IL‑13, 
Interleukin‑13; ATP, Adenosine Triphosphate; GTP, Guanosine triphosphate; cGMP, cyclic guanosine monophosphate; RAAS: Renin–Angiotensin–
Aldosterone System; Notch1, Notch homolog 1 translocation‑associated (drosophila)
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combination improved diastolic function better than 
val monotherapy, suggesting a role for enhanced car-
diac cyclic GMP signaling. Taken together, these stud-
ies suggest that sac/val is superior to val in reversing 
obesity-associated DD, and is an attractive drug combi-
nation for the treatment of early asymptomatic diastolic 
dysfunction in obesity and prevention of progression of 
CVD leading to HFpEF.
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